Compare Ascendis Pharma A/S (ASND) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Williams-Sonoma, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Williams-Sonoma, Inc. trades at $221.75 (market cap $26.11B). The key difference: Williams-Sonoma, Inc. is the larger of the two by market cap, and Williams-Sonoma, Inc. pays a 1.37% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WSM | |
|---|---|---|
Market Cap | $17.74B | $26.11B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $240.06 |
52-Week Low | $163.32 | $163.62 |
Enterprise Value | $18.11B | $26.95B |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Williams-Sonoma (WSM) trades at $221.75, up 0.9% with a bullish technical signal. The company demonstrates strong profitability with 46.1% gross margins and 54% ROE, though revenue has declined from $8.7B in 2023 to $7.7B in 2025. Recent quarterly earnings have consistently beaten expectations, and the company maintains a $0.76 quarterly dividend. Analyst consensus is mixed with 29% buy ratings but a $215.50 price target below current levels.
WSM faces headwinds from revenue contraction and competitive pressures in home furnishings, though strong margins and consistent earnings beats provide support. The stock trades at premium valuations (P/E 24.9, P/S 3.4) requiring sustained execution. Near-term direction hinges on Q2 2026 earnings due next, with technical support at $217 and resistance at $223.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
